Genoway SA
Genoway SA is a biotechnology company focused on the development of innovative diagnostic solutions for the healthcare industry.
Business. Genoway SA (ALGEN.PA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Genoway SA (ALGEN.PA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Genoway's capital structure is characterized by a basic and diluted share count of 12,115,177 shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity position remains unassessed due to the absence of balance-sheet inputs and lack of going-concern language in source documents.
Profitability and return metrics are not available for Genoway, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This absence of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is not possible to assess the diversification of Genoway's revenue streams or its exposure to specific markets.
Growth trajectory is also unclear, as the outlook for the current and next fiscal years does not include numeric deltas or revenue projections. The absence of historical revenue data further limits the ability to assess the company's growth potential.
Risk factors include the unassessed liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the lack of detailed capital structure data means that potential dilution sources cannot be fully evaluated.
Recent events and filings do not provide additional insights into the company's operations or strategic direction. The absence of transcripts or detailed disclosures limits the ability to assess management's guidance or investor sentiment.
- Genoway operates in the healthcare diagnostics segment with a focus on biotechnology.
- The company's liquidity position is unassessed, raising concerns about short-term financial stability.
- No profitability metrics are available, making it difficult to evaluate performance against industry standards.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into business diversification.
- Analysts have issued a strong buy recommendation with a mean price target of 4.40 EUR.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €21.0M, −4,8% YoY.
- ▍Revenue €21.0M, −4,8% YoY
Revenue €22.1M, +10,0% YoY; Operating income +2,4% YoY.
- ▍Revenue €22.1M, +10,0% YoY
- ▍Operating income +2,4% YoY
- ▍Net income +16,8% YoY
- ▍Free cash flow −9,0% YoY
- ▍Net margin 8.3%
Revenue €20.0M, +17,6% YoY; Operating income +48,0% YoY.
- ▍Revenue €20.0M, +17,6% YoY
- ▍Operating income +48,0% YoY
- ▍Net income +101,5% YoY
- ▍Free cash flow +86,4% YoY
- ▍Net margin 7.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Genoway SA Market data — financials · 2026-05-27
- Genoway SA Market data — analyst estimates · 2026-05-27